Individualization of drug dosage regimens
- PMID: 3301171
Individualization of drug dosage regimens
Abstract
Individualizing drug dosage regimens is a common application of therapeutic drug monitoring. For drugs with a narrow therapeutic index or variable pharmacokinetic parameters, pharmacokinetic-based dosing can be useful. Pharmacokinetic methods that can aid the clinician in targeting for desired drug serum concentrations have been developed and clinically evaluated. These methods range from single nomograms or pharmacokinetic equations in which no serum concentrations are necessary to more complex techniques requiring serum concentration data and computer support. The most recently developed technique, Bayesian forecasting, may allow for more precise dosage individualization.
Similar articles
-
[Individualization of drug dosage by therapeutic monitoring in plasma and the application of pharmacokinetic principles].J Clin Chem Clin Biochem. 1983 Nov;21(11):649-58. J Clin Chem Clin Biochem. 1983. PMID: 6655441 German.
-
Appropriateness of sampling times for therapeutic drug monitoring.Am J Hosp Pharm. 1984 Sep;41(9):1796-801. Am J Hosp Pharm. 1984. PMID: 6496515
-
Therapeutic drug monitoring and pharmacokinetic dose prediction methods.Wien Klin Wochenschr Suppl. 1992;191:12-5. Wien Klin Wochenschr Suppl. 1992. PMID: 1509745 Review.
-
Bayesian approaches in pharmacokinetic decision making.Clin Pharm. 1984 Sep-Oct;3(5):525-30. Clin Pharm. 1984. PMID: 6488735
-
Individualization of drug dosage--past, present and future.Med Monatsschr Pharm. 2003 May;26(5):150-2. Med Monatsschr Pharm. 2003. PMID: 12784502 Review.
Cited by
-
Benchmarking therapeutic drug monitoring software: a review of available computer tools.Clin Pharmacokinet. 2013 Jan;52(1):9-22. doi: 10.1007/s40262-012-0020-y. Clin Pharmacokinet. 2013. PMID: 23196713 Review.
-
Clinical pharmacokinetics in infants and children. A reappraisal.Clin Pharmacokinet. 1989;17 Suppl 1:29-67. doi: 10.2165/00003088-198900171-00005. Clin Pharmacokinet. 1989. PMID: 2692939 Review.
-
AstraZeneca COVID-19 vaccine: A possible risk factor for ischemic stroke and cerebral venous sagittal sinus thrombosis: A case series.Clin Case Rep. 2022 Jul 11;10(7):e6017. doi: 10.1002/ccr3.6017. eCollection 2022 Jul. Clin Case Rep. 2022. PMID: 35846901 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical